Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9902353 | 0.78 | RIPK1 (0.43) | RIPK1 | |
| SCHEMBL9903378 | 0.69 | PIK3CA (0.33) | PIK3CAPIK3CBPIK3CG | |
| SCHEMBL3276191 | 0.69 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL9902312 | 0.67 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL3280283 | 0.62 | MAPK1 (0.44) | RIPK1 | |
| SCHEMBL3646793 | 0.59 | USP30 (0.39) | RIPK1MKNK1MKNK2 | |
| SCHEMBL28796833 | 0.59 | HPGD (0.36) | — | |
| SCHEMBL17748270 | 0.58 | PARP1 (0.45) | RIPK1 | |
| SCHEMBL3280126 | 0.58 | RIPK1 (0.42) | RIPK1 | |
| SCHEMBL23798617 | 0.58 | CNR2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916549-B2 | Thienooxazepine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| EP-2463290-B1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20120196848-A1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-2463290-A1 | THIENOOXAZEPINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196848-A1 | THIENOOXAZEPINE DERIVATIVE | HTR2C, HTR2B, HTR2A | RIPK1 2833/4885PIK3CA 3110/4885PIK3CB 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.